A multinational, multicenter, single visit, exploratory pharmacogeneti
A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) trial
What it measured
Main measures
The primary endpoint is defined as the proportion of responders by group as defined by SNP markers.
Loading reviews and guidelines…
History
- In scope changed from true to false
Started
Oct 2009
Assembled by software from public sources.